期刊文献+

胃癌组织中VEGF、HER-2/neu的研究 被引量:1

Study of VEGF and HER-2/neu in gastric cancer
下载PDF
导出
摘要 目的研究血管内皮生长因子(VEGF)和表皮生长因子受体2(HER-2/neu)在胃腺癌组织中的表达及其与胃癌各临床病理特征、胃癌患者生存期之间的关系。方法通过回顾性研究,随访到有103例完整生存期的胃癌患者,应用免疫组化方法检测他们标本中VEGF、HER-2/neu的表达,并应用统计学方法分析检测结果与临床病理特征、生存期之间的关系。结果胃癌组织中VEGF、HER-2/neu的阳性表达率分别为46.6%、31.1%,胃正常组织中二者均无表达;VEGF、HER-2/neu表达与肿瘤的浸润深度、病理分期、淋巴结转移、远处转移相关(P<0.05);VEGF与HER-2/neu阳性表达与生存期相关。结论检测胃癌组织中VEGF、HER-2/neu表达有助于临床判断患者预后。 Objective To investigate the expression of vascular endothehal growth factor (VEGF) and epidermal growth factor receptor 2 (HER-2) in gastric cancer and their relationship with clinical pathologic character and with survival. Methods The expression of VEGF and HER-2/neu in gastric cancer were studied by immunohistochemical technique. Their detect outcome and clinical pathologic character were analyzed. Results In gastric cancer specimens, the positive rate of VEGF and HER-2/nen was 46.6% and 31.1% respectively. The expression of VEGF and HER-2/neu were not found in gastric normal tissue. The positive expression rate of VEGF and HER-2/neu were related to depth of invasion, clinical stage, lymph node and distant metastasis of gastric cancer patients ( P 〈 0.05 ). VEGF and HER-2/neu expression was related to survival time. Conclusion The expression of VEGF and HER-2/neu in gastric cancer tissues can shed light on the judgement of the prognosis.
出处 《山东医药》 CAS 北大核心 2008年第32期13-15,共3页 Shandong Medical Journal
基金 广东省自然科学基金资助项目(2004037050)
关键词 胃肿瘤 血管内皮生长因子 受体 表皮生长因子 靶向治疗 gastric cancer vascular endothelial growth factor receptor, epidermal growth factor targeted therapy
  • 相关文献

参考文献4

二级参考文献13

  • 1Maeda K, Chung YS, Onoda N, et al. Proliferating cell nuclear antigen labeling index of preoperative biopsy specimens in gastric carcinoma with special reference to prognosis [J]. Cancer, 1994,73(3):528~533.
  • 2Shimizu M, Saitoh Y, Itoh H, et al. Immunohistochemical staining of H-ras oncogene product in normal, benign and malignant human pancreatic tissue[J]. Hum Pathol, 1990, 21:607.
  • 3Noda H, Maehara Y, Irie K, et al. Increased proliferative activity caused by loss of p21 (WAF1/CIP1) expression and its clinical significance in patients with early-stage gastric carcinoma[J]. Cancer,2002, 94(7):2107~2112.
  • 4Mori M, Kakeji Y, Adachi Y, et al. The prognostic significance of proliferating cell nuclear antigen in clinacal gastric cancer [J].Surgery, 1993, 113(6):683~690.
  • 5Aoyagi K, Kohfuji K, Yano S, et al. Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreadingtype and penetrating-type gastric carcinoma [J]. Kurume Med J,2001, 48(3):197~200.
  • 6Garcia I, Vizoso F, Andicoechea A, et al. Clinical significance of epidermal growth factor receptor content in gastric cancer[J]. Int J Biol Markers, 2001, 16(3):183~188.
  • 7Koullias GJ, Kouraklis GP, Raftopoulos IS, et al. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas [J]. J Surg Oncol, 1996, 63(3):166~171.
  • 8Hirono Y, Tsugawa K, Fushida S, et al. Amplification of epidermal growth factor receptor gene and its relationship to survival in human gastric cancer[J]. Oncology, 1995, 52 (3):182~188.
  • 9Boivin GP, Molina JR, Ormsby I, et al. lesions in transfroming growth factor beta-1 heterozygous mice [J]. Lab Invest,1996, 74(2):513~518.
  • 10Takeno S, Wirtz HC, Lickvers K,et al. Transforming growth factor beta type Ⅱ receptor expression in gastric cancer: evidence for two independent subgroups[J]. Anticancer Res, 2002, 22(4):2247~2252.

共引文献24

同被引文献4

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部